In re Aratana Therapeutics Inc. Sec. Litig.
315 F. Supp. 3d 737
S.D. Ill.2018Background
- Aratana Therapeutics, a development-stage animal-pharmaceutical company, sought FDA approval and commercialization of ENTYCE (an appetite stimulant for dogs); plaintiffs purchased Aratana securities between March 16, 2015 and March 13, 2017.
- During the Class Period Aratana repeatedly announced expected commercialization timelines (mid-2016, late-2016, then early 2017) and disclosed it relied on third-party contract manufacturers and might need additional regulatory steps for manufacturing transfers.
- Aratana filed an administrative NADA and later filed manufacturing-related supplements; on February 2, 2017 the FDA/CVM requested additional information about Aratana’s proposed transfer of ENTYCE manufacturing, and Aratana announced a delay on February 6, 2017 (stock fell ~18%).
- Plaintiffs allege defendants made false or misleading statements and omissions about ENTYCE’s commercial readiness and lacked an FDA-approved commercial manufacturer; they assert §10(b)/Rule 10b-5 and §20(a) claims and allege insider trading and motives to avoid loan payments and support stock offerings.
- The district court considered the public filings, earnings calls, and alleged facts, and dismissed the Amended Complaint in full for failure to plead falsity and scienter with the particularity required by Rule 9(b) and the PSLRA.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Falsity of timeline and commercialization statements | Plaintiffs: statements promising ENTYCE launch were misleading because Aratana lacked an FDA‑approved commercial manufacturer and would need further approvals | Aratana: statements were opinion/forward‑looking, accompanied by detailed cautionary disclosures about reliance on contract manufacturers and need for approvals; some statements were puffery | Court: Most statements were nonactionable puffery or protected forward‑looking opinions with meaningful cautionary language; plaintiffs failed to plead concrete false historical facts |
| Omission theory re: manufacturing transfer and PAS | Plaintiffs: defendants concealed that a manufacturing transfer would require a PAS and that CVM inquiries were likely, rendering statements misleading | Defendants: disclosures repeatedly warned that transfers and third‑party approvals could delay commercialization; Aratana disclosed transfers and planned FDA filings | Court: Disclosures sufficiently warned investors of the risk; omission theory fails because risk was disclosed and not concealed |
| Scienter (motive/opportunity or recklessness) | Plaintiffs: insider sales, desire to avoid loan payments, and to ensure successful stock offerings show motive; repeated timeline revisions = recklessness | Defendants: insider sales were pursuant to 10b5‑1 plans and not suspicious when contextualized; generalized motives insufficient; no internal documents or CWs showing knowledge | Court: Plaintiffs failed to allege concrete motive or strong circumstantial evidence of conscious misbehavior; insider trades and other allegations do not create a compelling inference of scienter |
| §20(a) control-person liability | Plaintiffs: individual defendants (CEO/CFO) controlled Aratana and are liable as culpable participants | Defendants: primary §10(b) claim fails, so §20(a) cannot stand | Held: §20(a) claims dismissed for failure to plead a primary violation |
Key Cases Cited
- Bell Atl. Corp. v. Twombly, 550 U.S. 544 (pleading must be plausible)
- Ashcroft v. Iqbal, 556 U.S. 662 (courts need not accept legal conclusions)
- ATSI Commc'ns, Inc. v. Shaar Fund, Ltd., 493 F.3d 87 (heightened pleading for securities fraud)
- Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (standard for strong inference of scienter)
- Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (material misstatements/omissions and loss causation standard)
- Omnicare, Inc. v. Laborers Dist. Council Const. Indus. Pension Fund, 575 U.S. 175 (when opinions are actionable; omissions making opinions misleading)
- Tongue v. Sanofi ("Sanofi II"), 816 F.3d 199 (Second Circuit applying Omnicare to opinion‑based statements)